Treatment of Premenstrual Dysphoric Disorder: Therapeutic Challenges

  title={Treatment of Premenstrual Dysphoric Disorder: Therapeutic Challenges},
  author={T. Pearlstein},
  journal={Expert Review of Clinical Pharmacology},
  pages={493 - 496}
  • T. Pearlstein
  • Published 2016
  • Medicine
  • Expert Review of Clinical Pharmacology
Emotional, behavioral, and physical symptoms that occur in the premenstrual phase lie on a continuum. Premenstrual dysphoric disorder (PMDD), categorized in Depressive Disorders in the DSM-5, represents the severest symptoms and occurs in 1.8–5.8% of menstruating women [1]. To meet the PMDD criteria, at least 5 out of 11 possible symptoms must be present in the premenstrual phase; these symptoms should be absent shortly following the onset of menses; and at least one of the five symptoms must… Expand

Topics from this paper

Premenstrual Dysphoric Disorder Without Comorbid Psychiatric Conditions: A Systematic Review of Therapeutic Options
Based on the results of the qualitative synthesis, the best therapeutic option in the treatment of adult PMDD patients free of other mental disorders are selective serotonin reuptake inhibitor antidepressants and low doses of oral estroprogestins. Expand
Association between premenstrual dysphoric disorder and perinatal depression: a systematic review
Premenstrual dysphoric disorder (PMDD) affects 1.2 to 5% of women of reproductive age. Besides significant suffering and social, occupational, and interpersonal impairment, it has been suggested thatExpand
An Osteopathic Approach to Diagnosing and Treating Perimenstrual Disorders
relevant OMT techniques are described, which encompass the five models of osteopathic medicine that can be used for specific perimenstrual symptoms of PMS, PMDD, and dysmenorrhea. Expand
The diagnosis and management of depression in the era of the DSM-5
The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) introduced several changes to the chapter on depressive disorders largely informed by advances in neuroscience, clinical and public health needs and difficulties identified with the previous DSM-IV classification system and criteria. Expand
Salvia officinalis Reduces the Severity of the Premenstrual Syndrome
Salvia officinalis is an effective alternative agent to reduce the severity of psychological and physical symptoms of PMS. Expand
Antidepressant drugs as emerging contaminants: Occurrence in urban and non-urban waters and analytical methods for their detection.
There is an urgent need to test the presence of antidepressant members of the MAOI and TCA groups and incorporating new degradation/immobilization technologies in WWTPs will be useful to stop the increasing occurrence of these drugs in the environment. Expand
The Relationship Between Premenstrual Syndrome and Personal Properties in Unıversity Students
Arastirma universite ogrencilerinde premenstrual sendrom ile kisilik ozellikleri arasindaki iliskiyi belirlemek amaciyla yapilmistir ve yuksek okullarinda orgun ogretimde ogrenim goren 2426 kiz ogrenci olusturmustur. Expand


Premenstrual Dysphoric Disorder and Severe Premenstrual Syndrome in Adolescents
Premenstrual syndrome can be ameliorated by education about the nature of the disorder, improving calcium intake, performing exercise and reducing stress, but to treat severe PMS or PMDD pharmacologic therapy is usually required. Expand
Premenstrual dysphoric disorder: evidence for a new category for DSM-5.
A move to the position of category, rather than a criterion set in need of further study, will provide greater legitimacy for the disorder and encourage the growth of evidence-based research, ultimately leading to new treatments. Expand
Premenstrual Dysphoric Disorder: Epidemiology and Treatment
Recent literature on potential contributors to premenstrual dysphoric disorder’s pathophysiology, including neurosteroids and stress, are presented, and potential treatment targets are explored. Expand
Clinical Subtypes of Premenstrual Syndrome and Responses to Sertraline Treatment
The PMS and premenstrual dysphoric disorder diagnoses have similar response to sertraline treatment, but symptom-based subtypes have significantly different responses to this treatment. Expand
Are there Differential Symptom Profiles that Improve in Response to Different Pharmacological Treatments of Premenstrual Syndrome/Premenstrual Dysphoric Disorder?
Re-analysis of available datasets from randomised clinical trials may shed more light on the notion that targeting women with specific premenstrual symptom profiles for specific treatment modalities would improve response rates beyond the current ceiling of approximately 60%, and improve understanding of the putative pathophysiological mechanisms underlying PMS and PMDD. Expand
The premenstrual symptoms screening tool (PSST) for clinicians
The PSST applies a necessary degree of measure of severity and impact of premenstrual symptoms, establishes quickly if women qualify for PMDD, and is less time consuming and more practical than two cycles of prospective charting. Expand
Psychotropic medications and other non-hormonal treatments for premenstrual disorders
Women going through the menopausal transition may need to adjust their antidepressant dosing regimen due to the change in frequency of menstruation and the efficacy of symptom-onset dosing needs further systematic study. Expand
Selective serotonin reuptake inhibitors for premenstrual syndrome.
The evidence supports the use of selective serotonin reuptake inhibitors in the management of severe premenstrual syndrome. Expand
Symptom-Onset Dosing of Sertraline for the Treatment of Premenstrual Dysphoric Disorder: A Randomized Clinical Trial.
A double-blind, placebo-controlled, multisite, parallel-group randomized clinical trial to determine the efficacy of symptom-onset dosing with the SRI sertraline hydrochloride for treatment of premenstrual dysphoric disorder and found that women with PMDD may not benefit from the onset of symptoms through the beginning of menses. Expand
Neuroimaging the Menstrual Cycle and Premenstrual Dysphoric Disorder
The present review scrutinized organizational and functional neuroimaging correlates of the menstrual cycle and premenstrual dysphoric disorder and supportive evidence of cyclic short-term structural and functional brain plasticity in response to gonadal hormonal modulation is provided. Expand